Sustainable and Efficient Platform Trial of New Therapeutic Development for Early Breast Cancer
Recruiting now · Phase 2
Conditions studied: Breast Cancer
In brief
Randomized phase II trial targeting early-stage breast cancer (stage II-III) applicable to preoperative chemotherapy (NAC), comparing standard treatment with multiple experimental treatments.
Key facts
- Study ID
- NCT06535893
- Run by
- Nagoya City University
- People needed
- 100
- Starts
- 2024-07-30
- Expected to finish
- 2040-06-30
- Last updated by the study team
- 2025-11-20
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Histologically or cytologically confirmed invasive breast carcinoma
- Stage II or III
- ECOG performance status of 0 or 1
- Age 18-80
You may not qualify if…
- Continuous systemic administration (oral or intravenous) of steroid drugs or other immunosuppressants.
- History or complication of interstitial lung disease or pulmonary fibrosis diagnosed by imaging or clinical findings.
- Infection requiring systemic treatment.
- Active double cancer (however, the following are not excluded: (1) Completely resected cancers: basal cell carcinoma, squamous cell carcinoma at clinical stage I, carcinoma in situ, mucosal carcinoma, superficial bladder carcinoma, (2) Gastrointestinal cancer that has been curatively resected by ESD or EMR, (3) Other cancers that have not recurred for more than 5 years).
Where it is running
- Nagoya City University — Nagoya, Aichi-ken, Japan (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.